From Yahoo Finance: 2025-04-02 09:48:00

The biotechnology industry is experiencing growth with a rebound in 2025, driven by AI-driven drug discovery and personalized medicine. The global biotech market is projected to grow by 13% from $483.0 billion in 2024 to $546.0 billion in 2025. Lower interest rates are expected to boost biotech companies by increasing cash flow for R&D and clinical testing.

Biotech is witnessing transformative growth in 2025, with genetic engineering, synthetic biology, and AI-driven drug discovery leading the way. RNA therapeutics, regenerative medicine, and groundbreaking treatments like CRISPR-Cas9 and mRNA vaccines are reshaping the industry. Biotech equities are attracting investor interest due to innovative advancements and strong market potential.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a key player in the biotech sector, focusing on rare genetic diseases and specialized therapies. With a strong financial performance in Q4 2024, the company reported total sales growth, increased profitability, and improved operational efficiency. BMRN anticipates revenue growth and increased efficiency in 2025, solidifying its position as a profitable biotech stock.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) ranks 7th in the list of most profitable biotech stocks to buy right now. The company’s financial success, dedication to rare diseases, and strong growth projections make it a top contender in the biotech industry. With ongoing clinical trials and a robust therapeutic pipeline, BMRN continues to innovate and drive growth in the sector.



Read more at Yahoo Finance: Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now?